Facial fat is important for filling out facial features and maintaining youthful appearance
In off-label discussions, commonly referenced ranges include: Semaglutide: approximately 0.050.125 mg weekly Tirzepatide: below 1 mg weekly For a closer look at typical low-dose ranges, see our tirzepatide microdosing chart
This attenuation is explained in part by shifting complier composition: As GLP-1 diffusion expands, the marginal patients induced into treatment become progressively healthier
Based on current clinical evidence, Mounjaro (tirzepatide) is generally the best tolerated of the available options, with lower rates of nausea compared to semaglutide at equivalent weight loss doses
A thorough discussion of your personal medical history with your doctor is crucial before starting any GLP-1 RA therapy
These approaches should be discussed with a healthcare professional to ensure they are appropriate for individual circumstances